Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201878 | 0.85 | CRHR1 (0.40) | CRHR1HSP90AA1HSP90AB1CASR | |
| SCHEMBL24170751 | 0.84 | CRHR1 (0.38) | CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL21917556 | 0.83 | CYP3A4 (0.33) | CRHR1CYP3A4 | |
| SCHEMBL18175188 | 0.82 | CYP3A4 (0.37) | CRHR1CYP3A4 | |
| SCHEMBL12889911 | 0.79 | CRHR1 (0.43) | CRHR1HSP90AA1HSP90AB1CASR | |
| SCHEMBL14268227 | 0.79 | LMNA (0.38) | CRHR1 | |
| SCHEMBL12015800 | 0.77 | CRHR1 (0.42) | CRHR1HSP90AA1HSP90AB1CASR | |
| SCHEMBL19726453 | 0.76 | CRHR1 (0.42) | CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL5716046 | 0.76 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL18503027 | 0.75 | ACHE (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2020-03-19 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | CRHR1 485/4885HSP90AA1 1778/4885HSP90AB1 2115/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | CRHR1 397/4885HSP90AA1 1602/4885HSP90AB1 2090/4885 |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | CRHR1 397/4885HSP90AA1 1602/4885HSP90AB1 2090/4885 |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | CRHR1 397/4885HSP90AA1 1602/4885HSP90AB1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.